Exenatide

Most approved GLP-1RAs are administered subcutaneously. Image credit: Getty Images / Steve Christo – Corbis A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine , investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide). The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery. Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk. The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%). To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: “Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.” Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m². Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma. Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms. GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes , including Alzheimer’s disease, addictive disorders and psychiatric disorders. GLP-1RAs have grown massively in recent years following the release of Novo Nordisk’s semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity , and Eli Lilly’s tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity. GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales. GlobalData is the parent company of Clinical Trials Arena.

GLP1类药物，绝对是全球最大热门。当前全球已上市的药物市场，主要是诺和诺德的司美格鲁肽和礼来的替尔泊肽之间的较量。而在国内市场，由于市场准入条件不同，价格，再加上咱们的特色情况，GLP1市场情况有点复杂。目前，国内共有11款GLP1类药品获批上市，每个产品各有特点，市场表现各不相同。这篇文章，就简单分享下这些产品的市场销售表现。1、艾塞那肽/艾塞那肽微球艾塞那肽注射液最早上市的GLP1，曾经，国内医院市场的销售额也超过1亿元，但毕竟硬伤太多，很快被利拉鲁肽、度拉糖肽拍死在沙滩上。2023年销售额跌倒两千万元。这个产品还有两个国产仿制，不知当年仿制药企业立项时，有没有注意到利拉鲁肽和司美格鲁肽的进展。艾塞那肽微球已被放弃，2022年后没有销售。2、利拉鲁肽注射液诺和诺德一出手，全球市场迅速碾压艾塞那肽，只是这几年在司美格鲁肽上市后，销售额才有所下降。中国市场和还在增长，医院市场最高销额接近20亿。国内已有中美华东、通化东宝、正大天晴、珠海联邦4个仿制获批。考虑到本品在基药目录以及国内的支付能力，未来，这个产品在中低端市场，仍然还有生命力。3、贝那鲁肽注射液国产首个GLP-1新药，当别人已经在开发一周一次的长效产品时，贝那鲁肽一天3次给药，竟然被获批了，竟然还获批了降糖、减重两个适应症，竟然医院市场还能有小几百万的销售额，这真是个奇迹啊。4、利司那肽注射液每日一次短效，降糖效果没有优势，心血管结局试验失败，利司那肽的失败，不可避免。赛诺菲也基本放弃了该产品。全球市场、国内市场销售也都基本清零。5、度拉糖肽注射液每周一次的长效制剂，明确的心血管获益证据。国内上市后销售额暴涨，已超过11亿元。6、聚乙二醇洛塞那肽注射液豪森的国产长效制剂，此前的市场销售还算给力吧！后面随着司美格鲁肽、替尔泊肽，以及国产新药上市，压力很大。7、司美格鲁肽注射液/片司美格鲁肽注射液绝对的王者，仅有降糖适应症在医保，也阻止不了产品大爆发，2024年去年预计超50亿元。司美格鲁肽片获批不久，暂无销售数据。8、替尔泊肽注射液2024年5月首次获批，降糖、减重两大适应症均已获批，和司美格鲁肽必有一战。9、依苏帕格鲁肽α注射液又一个国产长效GLP1，今年新获批，如果没有头对头的强有力临床数据，推广难度也不小啊。用摩熵药筛小程序，快速查询产品信息。